NCT02077959 - Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 3, 2014

Primary Completion Date

May 24, 2019

Study Completion Date

May 24, 2019

Conditions

Multiple Myeloma

Interventions

DRUG

lenalidomide

Given PO

BIOLOGICAL

pidilizumab

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus

Beth Israel Deaconess Medical Center, Boston